|
1
|
Rangachari D, Yamaguchi N, VanderLaan PA,
Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE,
Huberman MS, et al: Brain metastases in patients with EGFR-mutated
or ALK-rearranged non-small-cell lung cancers. Lung Cancer.
88:108–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Iuchi T, Shingyoji M, Sakaida T, Hatano K,
Nagano O, Itakura M, Kageyama H, Yokoi S, Hasegawa Y, Kawasaki K,
et al: Phase II trial of gefitinib alone without radiation therapy
for Japanese patients with brain metastases from EGFR-mutant lung
adenocarcinoma. Lung Cancer. 82:282–287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ahn MJ, Tsai CM, Yang JC, Shepherd FA,
Satouchi M, Kim DW, Bazhenova L, Hirashima T, Rukazenkov Y,
Cantarini M, et al: AZD9291 activity in patients with EGFR-mutant
advanced non-small cell lung cancer (NSCLC) and brain metastases:
Data from Phase II studies. Eur J Cancer. 51:S625–S626. 2015.
View Article : Google Scholar
|
|
4
|
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim
HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et al
AURA3 investigators, : Osimertinib or platinum-pemetrexed in EGFR
T790M-positive lung cancer. N Engl J Med. 376:629–640. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tallet AV, Azria D, Barlesi F, Spano JP,
Carpentier AF, Gonçalves A and Metellus P: Neurocognitive function
impairment after whole brain radiotherapy for brain metastases:
Actual assessment. Radiat Oncol. 7:772012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li MX, He H, Ruan ZH, Zhu YX, Li RQ, He X,
Lan BH, Zhang ZM, Liu GD, Xiao HL, et al: Central nervous system
progression in advanced non-small cell lung cancer patients with
EGFR mutations in response to first-line treatment with two
EGFR-TKIs, gefitinib and erlotinib: A comparative study. BMC
Cancer. 17:2452017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Togashi Y, Masago K, Masuda S, Mizuno T,
Fukudo M, Ikemi Y, Sakamori Y, Nagai H, Kim YH, Katsura T, et al:
Cerebrospinal fluid concentration of gefitinib and erlotinib in
patients with non-small cell lung cancer. Cancer Chemother
Pharmacol. 70:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ballard P, Yates JW, Yang Z, Kim DW, Yang
JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, et al:
Preclinical comparison of osimertinib with other EGFR-TKIs in
EGFR-mutant NSCLC brain metastases models, and early evidence of
clinical brain metastases activity. Clin Cancer Res. 22:5130–5140.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hata AN, Niederst MJ, Archibald HL,
Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang
HE, Krishnamurthy Radhakrishna V, et al: Tumor cells can follow
distinct evolutionary paths to become resistant to epidermal growth
factor receptor inhibition. Nat Med. 22:262–269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sekine A and Satoh H: Paradigm shift of
therapeutic management of brain metastases in EGFR-mutant non-small
cell lung cancer in the era of targeted therapy. Med Oncol.
34:1212017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koba T, Kijima T, Takimoto T, Hirata H,
Naito Y, Hamaguchi M, Otsuka T, Kuroyama M, Nagatomo I, Takeda Y,
et al: Rapid intracranial response to osimertinib, without
radiotherapy, in nonsmall cell lung cancer patients harboring the
EGFR T790M mutation: Two Case Reports. Medicine (Baltimore).
96:e60872017. View Article : Google Scholar : PubMed/NCBI
|
